Skip to main content
SpringerLink
Log in

Measuring Quality of Life in Patients with Schizophrenia

  • Review Article
  • Measuring Quality of Life in Schizophrenia
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Summary

Schizophrenia is a chronic disabling illness that affects about 1 % of the population. It is a heterogenous disorder with variable aetiological. prognostic and treatment response patterns. Its course is generally long term, with acute psychotic exacerbations that may require hospitalisation. The cornerstone of clinical management is the use of antipsychotic (neuroleptic) medications. Although these are effective, they can cause adverse effects that may impact negatively on the functional status of the individual.

Early studies of quality of life in schizophrenia were mainly concerned with the development of techniques to identify patients’ needs in the community. Difficulties encountered in these studies included: lack of agreement on definition of quality of life: lack of appropriate integrative conceptual models; concerns about reliability of patients’ self-reports about their quality of life; and the lack of standardised quality-of-life measures appropriate for schizophrenia.

A number of disease-specific or generic scales have subsequently been used for measurement of quality of life in schizophrenia. The list of disease-specific scales is extensive: unfortunately, many of them were used only in a single study or their psychometric properties were not specified. Generic scales can be applied across various types and severity of illness, as well as in different health interventions across demographic and cultural groups.

Medication costs in schizophrenia represent only a small fraction of the total cost of the illness. However, pharmacoeconomic studies have attracted much interest as a result of the high cost of newly introduced medications and of concern about the limitations of antipsychotic medications, particularly their adverse effects, as exemplified by the reintroduction of c10zapine for the treatment of refractory schizophrenia. Few studies have combined quality-of-life measures with cost analysis in schizophrenia; a number of these have methodological shortcomings. Many studies are retrospective in nature, and in most the number and length of hospitalisations has been used as the parameter for cost analysis, which can introduce bias depending on the varying approaches to hospitalisation.

We conclude that the following factors are important in choosing or developing a quality-of-life measure for schizophrenia: quality of life is a multidimensional concept that has to be reflected in its measurement; the scale has to be appropriate for the purpose as well as the population studied: measurement has to include patients’ self-reports about their quality of life; measures should include only items that are relevant and expected to change; single-item global measures are useful only when combined with multidimensional measures; in developing new scales, psychometric properties have to be established as well as being field-tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shur E. The epidemiology of schizophrenia. Br J Hosp Med 1988; 40: 38–45

    PubMed  CAS  Google Scholar 

  2. Eaton WW. Update on the epidemiology of schizophrenia. Epidemiol Rev 1991; 13: 320–8

    PubMed  CAS  Google Scholar 

  3. Jablensky A, Sartorius N, Emberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med 1992; Suppl.20: 1–97

    Google Scholar 

  4. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5

    Article  Google Scholar 

  5. Castle DJ, Wessely S, Murray RM. Sell and schizophrenia: effects of diagnostic stringency and associates with premorbid variables. BrJ Psychiatry 1993; 162: 658–64

    Article  CAS  Google Scholar 

  6. Mayer C, Kalterborn G, Naber D. Age of onset in schizophrenia: relations to psychopathology and gender. Br J Psychiatry 1993; 162: 665–71

    Article  PubMed  CAS  Google Scholar 

  7. Loranger AW. Sell difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157–61

    Article  PubMed  CAS  Google Scholar 

  8. Goodpastor WA, Hare BK. Factors associated with multiple readmissions to an urban public psychiatric hospital. Hosp Community Psychiatry 1991; 42: 85–7

    PubMed  CAS  Google Scholar 

  9. Pablo RY, Kadlac KE, Arboleda-Aorez J. The readmission of psychotic patients to a general hospital psychiatry unit. Gen Hosp Psychiatry 1986; 8: 190–7

    Article  PubMed  CAS  Google Scholar 

  10. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medication: what are they and are they being achieved? CNS Drugs 1995; 4: 8–16

    Article  Google Scholar 

  11. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609–18

    PubMed  CAS  Google Scholar 

  12. Awad AG, Hogan TP, Voruganti LNP, et al. Patients’ subjective ellperiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 Suppl.3: 123–33

    PubMed  Google Scholar 

  13. Campbell A, Converse PE, Rogers WL. Subjective measures of well-being. Am Psychology 1976; 31: 117–24

    Article  CAS  Google Scholar 

  14. Campbell A. The sense of well-being in America. New York: McGraw-Hill, 1981

    Google Scholar 

  15. McCall S. Human needs and the quality of life. In: Shea WR, King Farlow J, editors. Values and quality of life. New York: Science History Publications, 1976: 6–24

    Google Scholar 

  16. World Health Organization. The constitution of the World Health Organization. WHO Chronicle 1947; 1: 29

    Google Scholar 

  17. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619–26

    Article  PubMed  CAS  Google Scholar 

  18. Lamb RH. The new asylums in the community. Arch Gen Psychiatry 1979; 36: 129–34

    Article  PubMed  CAS  Google Scholar 

  19. Bachrach LL. Deinstitutionalization: an analytic review and sociological perspective. Rockville (MD): National Institute of Mental Health, 1976

    Google Scholar 

  20. Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982; 139: 1271–6

    PubMed  CAS  Google Scholar 

  21. Lehman A. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369–73

    Article  PubMed  CAS  Google Scholar 

  22. Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Community Psychiatry 1991; 42: 752–4

    PubMed  CAS  Google Scholar 

  23. Levitt AJ, Hogan TP, Bucosky CM. Quality of life in chronically mentally ill patients in day treatment. Psychol Med 1990; 20: 703–10

    Article  PubMed  CAS  Google Scholar 

  24. Corten P, Mercier C, Pelc J. Subjective quality of life: clinical model for assessment of rehabilitation treatment in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994; 29: 178–83

    PubMed  CAS  Google Scholar 

  25. Lehman A, Possidente S, Hawker F. The quality of life of chronic patients in state hospital and in community residences. Hosp Community Psychiatry 1986; 37: 901–7

    PubMed  CAS  Google Scholar 

  26. Meltzer HY, Burnett S, Bastani B, et al. Effects of Sill months of c10zapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7

    PubMed  CAS  Google Scholar 

  27. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 43: 262–5

    PubMed  CAS  Google Scholar 

  28. Awad AG. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Press, 1995: 735–47

    Google Scholar 

  29. Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res. In press

  30. Hogan TP, Awad HG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983; 13: 177–83

    Article  PubMed  CAS  Google Scholar 

  31. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347–52

    Article  PubMed  CAS  Google Scholar 

  32. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477–80

    Article  PubMed  Google Scholar 

  33. Van Putten T, May PRA, Marder S, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187–90

    Article  PubMed  Google Scholar 

  34. Naber D, Walther A, Kirshere T, et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Vienna: Springer Verlag, 1995: 111–22

    Google Scholar 

  35. Davidhizar ER. Can clients with schizophrenia describe feelings and beliefs about taking medications? J Adv Nurs 1985; 10: 469–73

    Article  PubMed  CAS  Google Scholar 

  36. Glazer W, Sholomskas D, Williams D, et al. Chronic schizophrenics in the community: are they able to report their social adjustment? Am J Orthopsychiatry 1982; 52: 166–71

    Article  PubMed  CAS  Google Scholar 

  37. Voruganti LPN. Quality of life measurement in schizophrenia: a study of the credibility of patients’ reports of self-rated quality of life [dissertation). Toronto: Institute of Medical Science, University of Toronto, 1996

    Google Scholar 

  38. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 37: 217–32

    Article  Google Scholar 

  39. Lehman AF, Bums BJ. Severe mental illness in the community. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 357–66

    Google Scholar 

  40. Pathek DS, Pleil AM, Funderburk FR. Quality of life and outcome assessment techniques — a resource guide. Kalamazoo, Michigan: Pharmacia Upjohn Publications, 1995

    Google Scholar 

  41. Stein LI, Test MA. Alternative to mental health treatment: I. conceptual model, treatment program and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392–97

    Article  PubMed  CAS  Google Scholar 

  42. Maim U, May PRA, Deneker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7: 477–87

    Google Scholar 

  43. Baker F, Intagliata J. Quality of life in the evaluation of community support systems. Eval Program Plann 1982; 5: 69–79

    Article  PubMed  CAS  Google Scholar 

  44. Bigelow DA, Brodsky G, Steward L, et al. The concept and measurement of quality of life as a dependent variable in evaluation of mental health services. In: Stahler GJ, Tash WR, editors. Innovative approaches to mental heahh evaluation. New York: Academic Press, 1982: 345–66

    Google Scholar 

  45. Lehman AF. Quality of life tool kit. Cambridge (MA): The Evaluation Center, 1995

    Google Scholar 

  46. Rosen A, Pavlovic H, Parker G. The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 1989; 15: 325–34

    PubMed  CAS  Google Scholar 

  47. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 1984; 10: 388–98

    PubMed  CAS  Google Scholar 

  48. Hurry J, Stuart E, Bebbington P, et al. Socio-demographic associations with social disablement in a community sample. Soc Psychiatry 1983; 18: 113–21

    Article  PubMed  CAS  Google Scholar 

  49. Stuart E, Wykes T. Assessment schedules for chronic psychiatric patients. Psychol Med 1987; 17: 485–93

    Article  Google Scholar 

  50. Becker M, Diamond R, Sainfon F. A new patient focused index for measuring quality of life in persons with severe and persisteol meOlal illness. Qual Life Res 1993; 2: 239–51

    Article  PubMed  CAS  Google Scholar 

  51. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987

    Google Scholar 

  52. Endicoll J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–71

    Article  Google Scholar 

  53. Diagnostic and Statistical Manual of Mental Disorders. 4th rev ed. Washington: American Psychiatric Association, 1994

  54. Bergner M, Bobbit RA, Caner WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  55. Ware Jr JE. The SF-36 health survey in quality of life and pharmacoeconomics in clinical trials. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincoll-Raven, 1996: 337–45

    Google Scholar 

  56. McHorney CA, Ware Jr JE, Lu R, et al. The MOS 36-item Shon-Form health survey (SF-36): III, tests of data quality scaling assumptions and reliability across diverse patient groups. Med Care 1994; 32: 40–66

    Article  PubMed  CAS  Google Scholar 

  57. Chambers LW. The McMaster heahh index questionnaire. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996: 267–79

    Google Scholar 

  58. Voruganti LNP, Heslegrave RJ, Awad AG. Sickness Impact Profile (SIP) as a measure of patients’ quality of life (QOLl in clinical trials involving antipsychotic drugs. 45th Annual Meeting of the American College of Neuropsychopharmacology; 1995 December 11-15; San Juan, Pueno Rico

    Google Scholar 

  59. Kozma A, Stones M. Social desirability in measures of subjective well-being: a systematic evaluation. J Gerontol 1987; 42: 56–9

    PubMed  CAS  Google Scholar 

  60. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatmeOl-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4

    PubMed  CAS  Google Scholar 

  61. Revicki DA, Luce BR, Weschler JM, et al. Clozapine’s costbenefits Icorrespondencel. Hosp Community Psychiatry 1991; 42: 93–4

    Google Scholar 

  62. Honigfeld G, Patin J. A two-year clinical and economic follow up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 881–5

    Google Scholar 

  63. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with c1ozapine. Hosp Community Psychialry 1994; 45: 261–4

    CAS  Google Scholar 

  64. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatmeOl of neuroleptic-resistant schizophrenics: impact on risk-benefit assessment. Am J Psychialry 1995; 152: 183–90

    CAS  Google Scholar 

  65. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic SChizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26

    PubMed  CAS  Google Scholar 

  66. Lindstrom E, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–12

    Article  PubMed  CAS  Google Scholar 

  67. Awad AG. Methodological and design issues in c1inicallrials of new neuroleptics — an overview. Br J Psychiatry 1993; 163 Suppl.22: 51–7

    Google Scholar 

  68. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medicallrealrneOlS in psychiatry. Psychopharmacol Bull 1995; 31: 57–65

    PubMed  CAS  Google Scholar 

  69. Data JL, Willke RJ, Barnes JR, et al. Re-engineering drug developmeol: integrating pharmacoeconomic research into the drug development process. Psychopharmacol Bull 1995; 31: 67–73

    PubMed  CAS  Google Scholar 

  70. Finon A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the Ireatment of schizophrenia. Pharmacoeconomics 1993; 4: 131–56

    Article  Google Scholar 

  71. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals in Canada. 1st ed. Ottawa: CCOHTA, 1994

    Google Scholar 

  72. Ministry of Health, Ontario, Canada. Ontario guidelines for economic analysis of pharmaceutical products. Toronto, Ontario: 1994

    Google Scholar 

  73. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354–61

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    A. George Awad & Ronald J. Heslegrave

  2. The Clarke Institute of Psychiatry, 250 College Street, Room 721, Toronto, Ontario, M5T 1R8, Canada

    A. George Awad

  3. Victoria Hospital, University of Western Ontario, London, Ontario, Canada

    Lakshmi N.P. Voruganti

  4. The Wellesley Hospital, Toronto, Ontario, Canada

    Ronald J. Heslegrave

Authors
  1. A. George Awad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lakshmi N.P. Voruganti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald J. Heslegrave
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Awad, A.G., Voruganti, L.N. & Heslegrave, R.J. Measuring Quality of Life in Patients with Schizophrenia. Pharmacoeconomics 11, 32–47 (1997). https://doi.org/10.2165/00019053-199711010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711010-00005

Keywords

Search

Navigation